ID: h-gap-5c6cec3e-m2
Hypothesis
plasma GFAP separates causal from compensatory states in: Blood-brain barrier permeability changes as early biomarkers for neurodegeneration
A longitudinal biomarker panel centered on plasma GFAP can distinguish harmful mechanisms from protective adaptation.
EvidencePending (0%)📖 6 cit🗣 2 debates✓ 6 support✗ 1 oppose
✓ All Quality Gates Passed
🧪 Overview
A longitudinal biomarker panel centered on plasma GFAP can distinguish harmful mechanisms from protective adaptation. The decisive experiment is to measure plasma GFAP before and after endothelial exosome profiling in stratified models.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Pericyte Stress<br/>PDGFR-beta Signaling Loss"]
B["Astrocyte Reactivity<br/>A1 Pro-Inflammatory Polarization"]
C["GFAP Upregulation<br/>Intermediate Filament Assembly"]
D["GFAP Release<br/>Plasma Biomarker Elevation"]
E["BBB Disruption<br/>Endothelial-Pericyte Uncoupling"]
F["SASP and Complement<br/>S100B and C1q Secretion"]
G["Neuronal Vulnerability<br/>Synapse Loss"]
A --> E
B --> C
C --> D
E --> B
E --> F
F --> G
D -.->|"biomarker of"| G
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style C fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style D fill:#1b5e20,stroke:#81c784,color:#81c784
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix5 supports1 contradicts
Supports
Novel NMDA-receptor antagonists ameliorate vanadium neurotoxicity.
Supports
The UNC5C T835M mutation associated with Alzheimer's disease leads to neurodegeneration involving oxidative stress and hippocampal atrophy in aged mice.
Supports
Metformin Mitigates Trimethyltin-Induced Cognition Impairment and Hippocampal Neurodegeneration.
Supports
AAV2-driven endothelin induces chronic reduced retinal blood flow/retinal ganglion cell loss in rats.
Supports
Protein misfolding and oxidative stress promote glial-mediated neurodegeneration in an Alexander disease model.
Contradicts
causal direction requires longitudinal perturbation
skeptic_round
📖 Linked Papers (16)Export BibTeX ↗
The UNC5C T835M mutation associated with Alzheimer's disease leads to neurodegeneration involving oxidative stress and hippocampal atrophy in aged mice.
Molecular neurodegeneration (2025) · PubMed:40468412 ↗
No figures
The UNC5C T835M mutation associated with Alzheimer's disease leads to neurodegeneration involving oxidative stress and hippocampal atrophy in aged mice.
Molecular neurodegeneration (2025) · PubMed:40468412 ↗
No figures
AAV2-driven endothelin induces chronic reduced retinal blood flow/retinal ganglion cell loss in rats.
Life science alliance (2025) · PubMed:40345829 ↗
No figures
AAV2-driven endothelin induces chronic reduced retinal blood flow/retinal ganglion cell loss in rats.
Life science alliance (2025) · PubMed:40345829 ↗
No figures
Metformin Mitigates Trimethyltin-Induced Cognition Impairment and Hippocampal Neurodegeneration.
Cellular and molecular neurobiology (2024) · PubMed:39441380 ↗
No figures
Metformin Mitigates Trimethyltin-Induced Cognition Impairment and Hippocampal Neurodegeneration.
Cellular and molecular neurobiology (2024) · PubMed:39441380 ↗
No figures
Dual-targeting of brain tumors with nanovesicles.
Bioimpacts (2023) · PubMed:36816997 ↗
No figures
Blood-Brain Barrier Overview: Structural and Functional Correlation.
Neural Plast (2021) · PubMed:34912450 ↗
No figures
Blood-Brain Barrier Disruption by Lipopolysaccharide and Sepsis-Associated Encephalopathy.
Front Cell Infect Microbiol (2021) · PubMed:34804998 ↗
No figures
Peripheral inflammation and blood-brain barrier disruption: effects and mechanisms.
CNS Neurosci Ther (2021) · PubMed:33381913 ↗
No figures
Peripheral inflammation and blood-brain barrier disruption: effects and mechanisms.
CNS neuroscience & therapeutics (2021) · PubMed:33381913 ↗
No figures
Novel NMDA-receptor antagonists ameliorate vanadium neurotoxicity.
Naunyn-Schmiedeberg's archives of pharmacology (2020) · PubMed:32388602 ↗
No figures
🏥 Translation
🧬 3D Protein Structure — PLASMA
No curated PDB or AlphaFold mapping for PLASMA yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for plasma GFAP from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for plasma GFAP.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.8%
Volatility
High
0.1687
Events (7d)
3
Price History
▼4.4%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF GFAP reflects harmful BBB-linked astrocyte activation, THEN BBB-stabilizing treatment in a pericyte-stress mouse model will lower plasma GFAP by >=20% within 8 weeks. | BBB stabilization reduces plasma GFAP >=20% and improves tracer leakage >=25% versus vehicle. | — no observation — | pending | 0.52 |
| IF plasma GFAP separates causal BBB injury from compensation, THEN GFAP will rise by >=15% only in participants with concurrent pericyte-stress extracellular vesicle signatures over 12 months. | GFAP annual increase >=15% is enriched in the high pericyte-stress EV group with odds ratio >=2.0. | — no observation — | pending | 0.57 |
🔮 Falsifiable Predictions (2)
pendingconf 57%
IF plasma GFAP separates causal BBB injury from compensation, THEN GFAP will rise by >=15% only in participants with concurrent pericyte-stress extracellular vesicle signatures over 12 months.
Predicted outcome: GFAP annual increase >=15% is enriched in the high pericyte-stress EV group with odds ratio >=2.0.
Falsification: GFAP rise is independent of pericyte-stress EV status or odds ratio <1.2.
pendingconf 52%
IF GFAP reflects harmful BBB-linked astrocyte activation, THEN BBB-stabilizing treatment in a pericyte-stress mouse model will lower plasma GFAP by >=20% within 8 weeks.
Predicted outcome: BBB stabilization reduces plasma GFAP >=20% and improves tracer leakage >=25% versus vehicle.
Falsification: GFAP reduction is <5% despite improved tracer leakage, or GFAP falls without BBB improvement.
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesis
| source | v1_phase_c_backfill |
| origin_type | debate_synthesis |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.